Pharmacell B.V. a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, announced in March that it finalized an agreement with ImmunoCellular Therapeutics Ltd. to support its pivotal phase 3 clinical trial in Europe with ICT-107. ICT 107 is a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the commonest and deadliest forms of brain cancer. Under the terms of the agreement, PharmaCell will perform a Technology Transfer from its US-based contract manufacturing partner to its newly acquired Geleen facility (The Netherlands), and support the subsequent clinical trial with ICT-107.